Literature DB >> 21632639

Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms.

Joseph P Glass1, Gulshan Parasher, Hugo Arias-Pulido, Rachel Donohue, Eric R Prossnitz, Lisa A Cerilli.   

Abstract

INTRODUCTION: Our study attempts to characterize mesothelin and GPR30 / estrogen receptor (ER) staining in pancreatic pathology.
MATERIALS AND METHODS: Immunohistochemical staining for mesothelin, GPR30, and ER was performed on a variety of pancreatic lesions.
RESULTS: 24 of 42 (57%) adenocarcinomas stained for mesothelin, while 0 of 16 non-carcinomas (0%) stained (p = 0.0000784). 35 of 39 (90%) adenocarcinomas stained for GPR30, while only 4 of 15 (27%) non-carcinomas stained (p = 0.0000036). Apart from stromal staining in one case of mucinous cystic neoplasm, no cases stained for ER. 27 of 37 (73%) adenocarcinoma fine needle aspirates were positive for mesothelin. DISCUSSION: GPR30 is more sensitive, but less specific than mesothelin for pancreatic adenocarcinoma. Mesothelin is detected in most adenocarcinoma fine needle aspirates. ER is rarely detected in pancreatic lesions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632639     DOI: 10.1177/1066896911409575

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  12 in total

1.  Diagnostic value of IMP3 in pancreatic cancer: a meta-analysis.

Authors:  Qianqian Wang; Tao Wang; Zhu Wang; Hong Zheng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

3.  Diagnostic value of mesothelinin pancreatic cancer: a meta-analysis.

Authors:  Lin Zhu; Yiling Liu; Guangyuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

4.  GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.

Authors:  Tapan K Nayak; Chinnasamy Ramesh; Helen J Hathaway; Jeffrey P Norenberg; Jeffrey B Arterburn; Eric R Prossnitz
Journal:  Mol Cancer Res       Date:  2014-07-16       Impact factor: 5.852

Review 5.  Nuclear receptors and pathogenesis of pancreatic cancer.

Authors:  Simone Polvani; Mirko Tarocchi; Sara Tempesti; Andrea Galli
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

6.  Mesothelin promotes cell proliferation in the remodeling of neonatal rat pancreas.

Authors:  Dan-Dan Yin; Liang-Hui You; Qing-Xin Yuan; Xiao-Di Liang; Ning Wang; Lin-Tao Wang; Li Yuan; Ke-Ming Wang; Wei De
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 7.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

8.  Inhibition of mesothelin as a novel strategy for targeting cancer cells.

Authors:  Kun Wang; Vidya Bodempudi; Zhengian Liu; Emma Borrego-Diaz; Farnaz Yamoutpoor; Anna Meyer; Richard A Woo; Weihong Pan; Arkadiusz Z Dudek; Mojtaba S Olyaee; Tuba Esfandyari; Faris Farassati
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

9.  G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.

Authors:  Whitney K Petrie; Megan K Dennis; Chelin Hu; Donghai Dai; Jeffrey B Arterburn; Harriet O Smith; Helen J Hathaway; Eric R Prossnitz
Journal:  Obstet Gynecol Int       Date:  2013-11-27

10.  Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.

Authors:  Gary Tozbikian; Edi Brogi; Kyuichi Kadota; Jeffrey Catalano; Muzaffar Akram; Sujata Patil; Alice Y Ho; Jorge S Reis-Filho; Britta Weigelt; Larry Norton; Prasad S Adusumilli; Hannah Yong Wen
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.